DNB Asset Management AS Purchases New Position in Recursion Pharmaceuticals, Inc. $RXRX

DNB Asset Management AS purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 313,707 shares of the company’s stock, valued at approximately $1,531,000. DNB Asset Management AS owned 0.07% of Recursion Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. TD Waterhouse Canada Inc. grew its position in shares of Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the last quarter. PFG Investments LLC bought a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at $53,000. Savant Capital LLC acquired a new position in Recursion Pharmaceuticals in the 3rd quarter valued at $54,000. NewEdge Advisors LLC increased its position in Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after buying an additional 2,428 shares during the period. Finally, Wealthfront Advisers LLC bought a new position in Recursion Pharmaceuticals during the 3rd quarter worth $57,000. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Bank of America cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $3.54 on Wednesday. The firm has a 50 day moving average of $4.15 and a 200-day moving average of $4.66. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.98 and a 12 month high of $7.18. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.84 billion, a PE ratio of -2.39 and a beta of 0.97.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business had revenue of $35.54 million for the quarter, compared to analyst estimates of $24.56 million. During the same quarter last year, the business posted ($0.53) EPS. The firm’s revenue for the quarter was up 671.7% on a year-over-year basis. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CFO Ben R. Taylor sold 13,426 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total value of $41,352.08. Following the sale, the chief financial officer directly owned 1,195,349 shares of the company’s stock, valued at $3,681,674.92. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares in the company, valued at approximately $2,695,105.35. This represents a 16.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 599,212 shares of company stock valued at $2,562,550. 8.43% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.